

Name: COMPLETE / SUBSTANCE : 2-Nitro-p-cresol / 4-methyl-2-nitrophenol / 119-33-5 Fri, 16 Dec 2022, 14:32:16+0900 /

Legal entity owner: National Institute of Health Sciences

Printing date: 2022-12-16T14:32:16.767+09:00

# Table of Contents

0/0	1
National Institute of Health Science	2
2-Nitro-p-cresol	
CORE	
1 General information	
1.10 Assessment approach (assessment entities)	
Assessment approach (assessment entities)	
OECD	
D Health Effects	
60 Acute toxicity: oral	
Acute toxicity: oral.001	
67 Repeated dose toxicity: oral	
Repeated dose toxicity: oral.001	
Repeated dose toxicity: oral.002	
70 Genetic toxicity in vitro	
Genetic toxicity in vitro.001	
Genetic toxicity in vitro.002	
71 Genetic toxicity in vivo	
Genetic toxicity in vivo.001	
73 Toxicity to reproduction	
Toxicity to reproduction.001	
DOMAIN	
Substance	. 40
Substance	40
References	. 41
Reference Substances	41
2-nitro-p-cresol	41
Test Materials	
2-Nitro-p-cresol	. 43
2-Nitro-p-cresol	. 44
Literatures	45
A reproduction/developmental toxicity screening test in rats treated orally	
with 2-nitro-p-cresol	. 45
In Vitro Chromosomal Aberration Test of 2-nitro-p-cresol on Cultured	
Chinese Hamster Cells.	46
Micronucleous test of 2-nitro-p-cresol on mouse	47
Reverse mutation test of 2-nitro-p-cresol in Bacteria	48
Single Dose Oral Toxicity Test of 2-nitro-p-cresol in Rats	. 49
Twenty-eight-day Repeat Dose Oral Toxicity Test of 2-Nitro-p-cresol in	
Rats	. 50
Legal Entities	
National Institute of Health Sciences	. 51

# **DOSSIER:**

**UUID:** 0

Dossier UUID:

Author:

Date: 2022-12-16T14:32:16.586+09:00

**Remarks:** 

# Dossier header –

# **Dossier submission type**

Name Complete table of contents

Version core 7.0

Name (given by user)

# Dossier subject -

Dossier subject 2-Nitro-p-cresol / 4-methyl-2-nitrophenol / 119-33-5

# Public name

Submitting legal entity National Institute of Health Science

Dossier creation date/time Fri, 16 Dec 2022, 14:32:16+0900

Used in category

# LEGAL\_ENTITY: National Institute of Health Science

UUID: f51e7b54-9211-4863-90ce-fcf8a155d647

**Dossier UUID:** 

Author:

Date: 2022-11-07T16:24:02.822+09:00

**Remarks:** 

# General information -

Legal entity name

National Institute of Health Science

# 2-Nitro-p-cresol

# CORE

# **General information**

Assessment approach (assessment entities)

FIXED\_RECORD: Assessment approach

UUID: dfa5593f-0296-3e44-9e65-f8823d5a8cea Dossier UUID: Author: Date: 2016-12-21T15:08:10.000+09:00 Remarks:

# OECD

# **Health Effects**

# Acute toxicity: oral

ENDPOINT\_STUDY\_RECORD: Acute toxicity: oral.001

UUID: 92069579-4fea-46b6-9947-0a4e625fdd42

**Dossier UUID:** 

Author:

Date: 2022-12-15T09:10:06.134+09:00

**Remarks:** 

# Administrative data

Endpoint acute toxicity: oral

Type of information experimental study

Adequacy of study key study

Robust study summary false

**Used for classification** false

**Used for SDS** false

**Reliability** 1 (reliable without restriction)

**Rationale for reliability incl. deficiencies** guideline study Reliability 1

# Data source -

# Reference

Single Dose Oral Toxicity Test of 2-nitro-p-cresol in Rats / MHLW, japan / study report

Data access data published

# Materials and methods -

Test guideline

Qualifier according to guideline

**Guideline** OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)

GLP compliance yes

Test type acute toxic class method

Limit test yes

# Test material

Test material information

2-Nitro-p-cresol

Specific details on test material used for the study CAS; 119-33-5

# Test animals -

**Species** rat common species

# Strain

Crj: CD(SD) rat

# Sex

female

# Details on test animals or test system and environmental conditions

- Source: Charles River Japan Inc.

- Age at the time of purchase: 7 weeks old

- Weight at dosing: Females, 190 - 192 g

- Fasting period before study: Approximately 16 hrs

- Housing: One animal/cage- Diet (e.g. ad libitum): Ad libitum except fasting period for 16 hrs before administration to 3 hrs after administration

- Water (e.g. ad libitum): Ad libitum

- Acclimation period: more than one week

ENVIRONMENTAL CONDITIONS

- Temperature (°C): 21-24

- Humidity (%): 36-59

- Ventilation (per hr): Approximately > 12 times

- Photoperiod (hrs light / hrs dark): 12/12

# Administration / exposure

# Route of administration oral: gavage

Vehicle corn oil

**Details on oral exposure** Test substance -Lot no.: FBR01 -Purity: 99.8% VEHICLE - Lot no.: V6K0677 produced by Nacalai Tesque, INC.. MAXIMUM DOSE VOLUME APPLIED: 10 ml/kg bw

# Doses

2000 mg/kg bw

### No. of animals per sex per dose

First time of administration: 3 females /dose Second time of administration: 3 females /dose

### **Control animals**

no

### Details on study design

- Duration of observation period following administration: 14 days

- Frequency of observations: Day 1 (day of administration): within 30 minutes and 1, 2, 3, 4, 5 and 6 hrs after administration. After day 2: once a day

- Frequency of weighing: on the day of administration (before administration), and 1, 3, 7, and 14 days after administration.

- Necropsy of survivors performed: Yes

The starting administration dose was set as 2000 mg/kg bw. No deaths were observed in the first administration; therefore, the second dose was also set as 2000 mg/kg bw.

Statistics

No

# **Results and discussion**

# Effect levels Key result true Sex female Dose descriptor LD50 Effect level > 2000 mg/kg bw Based on

act. ingr.

# Mortality

No deaths were observed in first and second times.

# **Clinical signs**

other: Decreased spontaneous movement was observed 30 min-4 hrs after administration in all anima ls.

# Gross pathology

No changes related to the test substance were observed in first and second times.

# Applicant's summary and conclusion

# Conclusions

The LD50 value was considered to be more than 2000 mg/kg bw for female rats.

# Repeated dose toxicity: oral

# ENDPOINT\_STUDY\_RECORD: Repeated dose toxicity: oral.001

UUID: IUC5-4b770d28-4eb4-4888-b89e-a27937fe34e8

Dossier UUID:

Author:

Date: 2022-12-16T14:25:48.717+09:00

**Remarks:** 

# Administrative data

### Endpoint

short-term repeated dose toxicity: oral

Type of information experimental study

Adequacy of study key study

Robust study summary false

**Used for classification** false

**Used for SDS** false

**Reliability** 1 (reliable without restriction)

**Rationale for reliability incl. deficiencies** other: The study was conducted in accordance with Test Guidelines and under GLP

### **Cross-reference**

**Reason / purpose for cross-reference** reference to other study

Remarks 7.5.1 Repeated dose toxicity: oral.002

# Data source -

# Reference

Twenty-eight-day Repeat Dose Oral Toxicity Test of 2-Nitro-p-cresol in Rats / MHLW, Japan / publication

Data access data published

# Materials and methods

# Test guideline

**Qualifier** according to guideline

### Guideline

other: other guideline: Guideline for 28-Day Repeated Dose Toxicity Test in Mammalian Species (Ch emical Substances Control Law of Japan)

### Qualifier

equivalent or similar to guideline

# Guideline

OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)

GLP compliance

yes

# Test material -

Test material information

2-Nitro-p-cresol

# Test animals

**Species** rat common rodent species

Strain other: Crl:CD(SD)

Sex male/female

# Details on test animals or test system and environmental conditions

TEST ANIMALS

- Source: Charles River Japan, Inc.
- Age at study initiation: 5 weeks old
- Weight at study initiation: male 161 g (146-173 g), female 144 g (130-154 g)
- Housing: Animals were individually housed in a metallic cage with wire mesh bottoms
- Diet: Solid feed (MR stock: Nosan Corporation) was given ad libitum.
- Water: Tap water was given ad libitum.
- Acclimation and quarantine period:7-8 days
- ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22±3 (actual temperature: 22.0-22.6 °C)
- Humidity (%): 55±10% (actual humidity: 55-62%)
- Air changes (per hr): 10-15
- Photoperiod (hrs dark / hrs light): 12 hr dark/12 hr light (light: 7:00~19:00)

# Administration / exposure

# Route of administration

oral: gavage

Vehicle olive oil Analytical verification of doses or concentrations yes

**Duration of treatment / exposure** 28 days

Frequency of treatment once a day

### Doses / concentrations

### Remarks

Doses / Concentrations: 0, 15, 60, 250, 1000 mg/kg bw/day Basis: actual ingested

# No. of animals per sex per dose

10/sex (0, 1000 mg/kg bw/day) 5/sex (15, 60, 250 mg/kg bw/day)

### **Control animals**

yes, concurrent vehicle

### Details on study design

- Dose selection rationale: Doses in this test were set based on the results of the following study: 14day repeated dose oral toxicity test (CrI:CD(SD) rats, doses: 0 (olive oil), 10, 30, 100, 250, 500 or 1000 mg/kg bw/day). At 500 mg/kg/day and higher, sedation and salivation, and tendency of urine oxidatio n were observed in both sexes. At 1000 mg/kg/day, anemia and changes in liver functions were observed. At 250 mg/kg/day and higher, an increasing tendency on the liver weight was observed in both sexes. On the basis of these effects, a dose level of 1000 mg/kg was selected as the maximum dose expecting to induce the toxic changes, and then dose levels of 250, 60 and 15 mg/kg bw/day were selected, in accordance with a common ratio of approximately 4.

- Rationale for animal assignment (if not random): Body weight-balanced randomization

- Post-exposure recovery period in satellite groups: 14 days

# **Examinations**

### Observations and examinations performed and frequency

CLINICAL OBSERVATIONS: Yes

- Time schedule: every day during the administration (4 times a day) and recovery periods (at least once a day)

### DETAILED CLINICAL OBSERVATIONS: Yes

The functional observational battery testing (FOB) was performed on all animals. Among the me asures in the FOB, detailed clinical observations were made before the initiation of dosing. Thereafter, detailed clinical observations were made once a week in dosing and recovery periods. Sensory motor reflexes, forelimb and hindlimb grip strengths, and motor activity were measured on week 4 of administration period (main/recovery group animals) and week 2 of recovery period (recovery group animals).

### BODY WEIGHT: Yes

- Time schedule for examinations: Before administration (on days 1, 7, 14, 21 and 28 of the admi nistration period, days 7 and 14 of the recovery period) and the necropsy days after completion of e very period.

FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):

- Food consumption: Yes. Once a week for 24-h (males: on days 5, 12, 19 and 26 of the administratio n period and days 5 and 12 of the recovery period. females: on days 4, 11, 18 and 25 of the administ ration period and days 4 and 11 of the recovery period)

OPHTHALMOSCOPIC EXAMINATION: No

HAEMATOLOGY: Yes

- Time schedule for collection of blood: the after completion of the administration and recovery perio ds

- Anaesthetic used for blood collection: ether

- Animals fasted: Yes (overnight)

- How many animals: all animals

# CLINICAL CHEMISTRY: Yes

- Time schedule for collection of blood: the day after completion of the administration and recovery periods

- Anaesthetic used for blood collection: ether

- Animals fasted: Yes (overnight)

- How many animals: all animals

**URINALYSIS: Yes** 

- Time schedule for collection of urine: on weeks 4 of the administration period and weeks 2 of the recovery period.

- Metabolism cages used for collection of urine: Yes NEUROBEHAVIOURAL EXAMINATION: No

# Sacrifice and pathology

GROSS PATHOLOGY: Yes

ORGAN WEIBHT: Yes [brain, pituitary gland, thyroid, adrenal, spleen, heart, liver, kidney, thymus, testis, epididymis, ovary]

HISTOPATHOLOGY: Yes [brain (cerebrum, cerebellum and medulla oblongata), pituitary gland, spinal cord (cervical, thoracical, lumber), thymus, thyroid (including parathyroid), adrenal glands, spleen, he art, stomach, liver, duodenum, jejunum, ileum (including Peyer's patches), cecum, colon, rectal, mes enteric lymph nodes, submandibular lymph nodes, trachea, lung, kidney, bladder, testis, epididymis, prostate, seminal vesicles, ovary, uterus, vagina, eye, bone marrow (femur) and the sciatic nerve. (see tables in the study report.)

### Statistics

As for parametric data (grip strength, locomotor activity, body weight, body weight gain, food consu mption, hematology and clinical chemistry data, organ weights), the values of means and standard deviations were calculated per group. When more than three groups exist in the test group, Bartlett test for variance was done, and if the variance was homogenous, ANOVA was applied. If the variance was not homogenous or data was non-parametric (differential WBC percentage, urinalysis data), Kruskal-Wallis rank sum test was used. Consequently, if the result was significant, Dunnett multiple comparison or Dunnett-typed method was used for detection of statistical significance against contr ol group. When the number of the test group was two, F-test was used as for parametric data. Then, s tudent's t-test or Aspin-Welch's t-test was applied depending on the result of homogeneity of variance. While, as for non-parametric data, Man-Whitney's U-test was applied. Furthermore, as for categorized data (incidence of abnormal findings in clinical observation, detailed observation, sensory functional examination, necropsy and histopathology), Fischer's exact test was used. In any tests, level of signi ficance was set at 5%.

# **Results and discussion**

# **Results of examinations**

**Clinical signs** effects observed, treatment-related

**Description (incidence and severity)** (see Details on results)

Mortality mortality observed, treatment-related

**Description (incidence)** (see Details on results)

Body weight and weight changes no effects observed

Food consumption and compound intake (if feeding study) no effects observed

Haematological findings effects observed, treatment-related

**Description (incidence and severity)** (see Details on results)

**Clinical biochemistry findings** effects observed, treatment-related

**Description (incidence and severity)** (see Details on results)

**Urinalysis findings** effects observed, treatment-related

**Description (incidence and severity)** (see Details on results)

Behaviour (functional findings) no effects observed

**Description (incidence and severity)** (see Details on results)

Organ weight findings including organ / body weight ratios effects observed, treatment-related

**Description (incidence and severity)** (see Details on results)

**Gross pathological findings** effects observed, treatment-related

**Description (incidence and severity)** (see Details on results)

Histopathological findings: non-neoplastic effects observed, treatment-related

**Description (incidence and severity)** (see Details on results)

Details on results CLINICAL SIGNS AND MORTALITY At 250 mg/kg bw/day and higher, sedation and ptosis were observed in both sexes. Transient salivation was observed in both sexes at 1,000 mg/kg bw/day. Soiled fur in one female and reddish tear in one male were observed at 1,000 mg/kg bw/day.

### NEUROBEHAVIOUR

Clinical signs in detailed observation: No effects. Sensory/reflex function test: No effects. Grip strength: In the recovery period, high value of hindlimb strength in males and low value of forelimb strength in female were observed. (These were within background date.) Motor activity: No effects.

BODY WEIGHT AND WEIGHT GAIN: No effects. FOOD CONSUMPTION: No toxicological effects.

### HAEMATOLOGY

At 1,000 mg/kg bw/day, low values of Hb, Ht and MCHC, and high values of Ret were observed in males and females, and high value of APTT was observed in females. At the end of recovery period, high values of MCV and MCH, and low value of MCHC were observed in males.

### CLINICAL CHEMISTRY

At 1,000 mg/kg bw/day, high values of Alb, A/G, T-Cho, and K in males, and high values of  $\gamma$ -GTP and T-Bil in females were observed. At the end of recovery period, high value of Na was observed in males.

### URINALYSIS

Pale yellow color was observed at 250 mg/kg bw/day and higher in males and females. At 1,000 mg/ kg bw/day, low value of pH were observed in males and females. In the recovery period, low value of specific gravity was observed in males.

### ORGAN WEIGHTS

At 250 mg/kg bw/day and higher, sedation and ptosis were observed in both sexes. Increase in the liver weight was observed at 250 mg/kg bw/day and higher in females and at 1,000 mg/kg bw/day in males. Furthermore, increases in the kidney weight in males and spleen weight in both sexes were observed at 1,000 mg/kg bw/day.

### GROSS PATHOLOGY

At 1,000 mg/kg bw/day, blackish color of the spleen was observed in males and females at the ends of administration and recovery periods.

### HISTOPATHOLOGY: NON-NEOPLASTIC

Histopathological examinations revealed hypertrophy of hepatocytes at 250 mg/kg bw/day and higher in females. At 1,000 mg/kg bw/day, increase in the extramedullary hematopoiesis and brown pi gmentation in the spleen was observed in both sexes. Additionally in males, hypertrophy of hepatocyt es in the liver was observed at 1,000 mg/kg bw/day. Moreover, an increase in hyaline droplets contai ning a2u-globulin in the renal proximal tubular epithelium in the kidney was observed in males at the same dose. These changes, except brown pigmentation in the spleen, tended to resolve after the rec overy period.

(See tables in the full report for more details)

# **Effect levels**

Key result false

Dose descriptor NOAEL

# Effect level

60

mg/kg bw/day (actual dose received)

Based on test mat.

**Sex** male/female

# Basis for effect level

other: see 'Remark'

At 250 mg/kg bw/day and higher, sedation and ptosis were observed in both sexes. Increase in the liver weight was observed at 250 mg/kg bw/day and higher in females and at 1,000 mg/kg bw/day in males. Histopathological examinations revealed hypertrophy of hepatocytes at 250 mg/kg bw/ day and higher in females.

# Target system / organ toxicity -

Key result false

Critical effects observed not specified

# Any other information on results incl. tables -

Figures and Tables (in English) are available in the following full report of the study.

http://dra4.nihs.go.jp/mhlw\_data/home/pdf/PDF119 -33 -5b.pdf

# Applicant's summary and conclusion

# **Executive summary**

A 28-day repeated-dose toxicity test was performed according to the Japanese guideline (similar to OECD TG 407). Male and female rats (5 animals/sex/dose) were administered 2-nitro-p-cresol at 0, 15, 60, 250, and 1,000 mg/kg bw/day. In addition, both sexes (5 animals/sex/dose) were administered 0 and 1,000 mg/kg bw/day of this substance for 28 days and examined after a 14-day recovery period. At 250 mg/kg bw/day and higher, sedation and ptosis were observed in both sexes. Increase in the liver weight was observed at 250 mg/kg bw/day and higher in females and at 1,000 mg/kg bw/day in males. Furthermore, increases in the kidney weight in males and spleen weight in both sexes were observed at 1,000 mg/kg bw/day. Histopathological examinations revealed hypertrophy of hepatocytes at 250 mg/ kg bw/day and higher in females. At 1,000 mg/kg bw/day, increase in the extramedullary hematopoiesis and brown pigmentation in the spleen was observed in both sexes. Additionally in males, hypertrophy of hepatocytes in the liver was observed at 1,000 mg/kg bw/day. Moreover, an increase in hyaline droplets containing a2u-globulin in the renal proximal tubular epithelium in the kidney was observed in males at the same dose. These changes, except brown pigmentation in the spleen, tended to resolve after the recovery period. On the basis of these effects, NOAEL for repeated-dose toxicity was determined to be 60 mg/kg bw/day in male and female rats.

### ENDPOINT\_STUDY\_RECORD: Repeated dose toxicity: oral.002

UUID: IUC5-c2b1b0b7-0568-4483-b21c-54cfa1d1f5a7

**Dossier UUID:** 

Author:

Date: 2022-12-16T14:27:08.815+09:00

**Remarks:** 

# Administrative data

### Endpoint

repeated dose toxicity: oral combined repeated dose and reproduction / developmental screening deactivated phrase

**Type of information** experimental study

Adequacy of study key study

Robust study summary false

**Used for classification** false

**Used for SDS** false

**Reliability** 1 (reliable without restriction)

Rationale for reliability incl. deficiencies other: GLP guideline study

# Cross-reference

**Reason / purpose for cross-reference** reference to same study

**Remarks** 7.8.1 Toxicity to reproduction.001

**Reason / purpose for cross-reference** reference to other study

**Remarks** 7.5.1 Repeated dose toxicity: oral.001

# Data source

### Reference

A reproduction/developmental toxicity screening test in rats treated orally with 2-nitro-p-cresol / MHLW, Japan / study report

Data access data published

# Materials and methods

# Test guideline

**Qualifier** according to guideline

Guideline

other: OECD TG 421: Reproduction/developmental toxicity screening test

Deviations no

GLP compliance yes

Limit test no

# Test material -

Test material information 2-Nitro-p-cresol

# Test animals -

**Species** rat common rodent species

Strain other: Crl: CD(SD)

Sex male/female

# Details on test animals or test system and environmental conditions

- TEST ANIMALS
- Source: Charles River Laboratories Japan, Inc. Tsukuba
- Age at study initiation: 10 weeks
- Weight at study initiation: Males: 392-474 (average 427) g; Females: 238-297 (average 270) g
- Housing: Steel wire-mesh cage (250 mm x 350 mm x 200 mm )
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 19 days

# ENVIRONMENTAL CONDITIONS

- Temperature (°C): 20-24
- Humidity (%): 33-69
- Air changes: 10-15 times / hr
- Photoperiod: 12 hrs dark / 12 hrs light (07:00-19:00)

# Administration / exposure

# Route of administration

oral: gavage

Vehicle olive oil

Analytical verification of doses or concentrations yes

### Duration of treatment / exposure

(P) Males: 42 days including 14 days pre-mating and mating periods, and thereafter 14 days (P) Femal es: 42-47 days including 14 days pre-mating, mating and gestation periods, and the days until day 4 of lactation. Infertile females: 40-53 days

# **Frequency of treatment**

Once/day, 7days/week

# Doses / concentrations

# Remarks

Doses / Concentrations: 0 (vehicle), 60, 250, and 1000 mg/kg bw/day Basis: actual ingested

# No. of animals per sex per dose

12 animals/sex/dose

# **Control animals**

yes, concurrent vehicle

### Details on study design

- Dose selection rationale: Doses in this test were set based on the results of the following study: 28day repeated dose oral toxicity test (doses: 0, 15, 60, 250, and 1000 mg/kg bw/day). At 250 mg/kg bw/day and higher, sedation and ptosis were observed in both sexes. Increase in the liver weight was observed at 250 mg/kg bw/day and higher in females and at 1,000 mg/kg bw/day in males. Furthermore, increases in the kidney weight in males and spleen weight in both sexes were observed at 1,000 mg/kg bw/day. Histopathological examinations revealed hypertrophy of hepatocytes at 250 mg/kg bw/day and higher in females. At 1,000 mg/kg bw/day, increase in the extramedullary hema topoiesis and brown pigmentation in the spleen was observed in both sexes. Additionally in males, hy pertrophy of hepatocytes in the liver was observed at 1,000 mg/kg bw/day. Moreover, an increase in hyaline droplets containing α2u-globulin in the renal proximal tubular epithelium in the kidney was o bserved in males at the same dose. These changes, except brown pigmentation in the spleen, tended to resolve after the recovery period.

On the basis of these effects, a dose level of 1000 mg/kg was selected as the maximum dose exp ecting to induce the toxic changes, and then dose levels of 250 and 60 mg/kg bw/day were selected as a middle dose and a minimum dose levels, respectively, in accordance with a common ratio of approximately 4.

- Rationale for animal assignment (if not random): Body weight-balanced randomization

# **Examinations**

### Observations and examinations performed and frequency

CAGE SIDE OBSERVATIONS: Yes - Time schedule: Males and females: 3 times/day BODY WEIGHT: Yes - Time schedule for examinations: Males: Days 1, 4, 8, 11, 15, 22, 25, 29, 32, 36, 39, 42, and the day of necropsy Females: Twice a week during the precopulation period (days 1, 4, 8, 11, and 15); gestation days 0, 4, 7, 11, 14, 17, and 20; lactation days 0 and 4; and the day of necropsy. For unmating females, 18, 22 and 25 in the mating period

FOOD CONSUMPTION: Yes Males: Days 1, 4, 8, 11, 15, 32, 36, 39, and 42 in dosing period Females: Days 1, 4, 8, 11, and 15; gestation days 1, 4, 7, 11, 14, 17, and 20; lactation days 2 and 4

HAEMATOLOGY: No CLINICAL CHEMISTRY: No

URINALYSIS: No

### Sacrifice and pathology

GROSS PATHOLOGY: Yes (see tables) HISTOPATHOLOGY: Yes (epididymis, prostate, seminal vesicle, testis, ovary, uterus, vagina, and gross abnormal sites)

### Other examinations

Organ weight: Testes and epididymides

### Statistics

3 or more groups: The data were analyzed for homogeneity of variance by the Bartlett test. If varian ces were homogeneous, data was analyzed by the Dunnett test, whereas heterogeneous data was analyzed by the steel test (p<0.05, two-sided).

2 groups: The data were analyzed for homogeneity of variance by the F test. If variances were homog eneous, data was analyzed by the Student t test, whereas heterogeneous data was analyzed by the Aspin-Welch t test (p<0.05, two-sided).

# Results and discussion -

# **Results of examinations** -

**Clinical signs** effects observed, treatment-related

**Description (incidence and severity)** At 1,000 mg/kg bw/day, ptosis and decreased locomotor activity were observed in both sexes.

# Mortality

mortality observed, treatment-related

### **Description (incidence)**

At 1,000 mg/kg bw/day, ptosis and decreased locomotor activity were observed in both sexes.

# Body weight and weight changes

no effects observed

# Food consumption and compound intake (if feeding study)

no effects observed

Food efficiency not examined

Water consumption and compound intake (if drinking water study) not examined

**Ophthalmological findings** not examined

Haematological findings not examined

Clinical biochemistry findings not examined

Urinalysis findings not examined

Behaviour (functional findings) not examined

Organ weight findings including organ / body weight ratios no effects observed

**Gross pathological findings** effects observed, treatment-related

**Description (incidence and severity)** see tables in the full report.

Histopathological findings: non-neoplastic effects observed, treatment-related

**Description (incidence and severity)** see tables in the full report.

Histopathological findings: neoplastic not examined

### **Details on results**

At 1,000 mg/kg bw/day, histopathological examinations revealed centrilobular hypertrophy of hepatocytes in the liver and increased extramedullary hematopoiesis in the spleen in both sexes.

# Effect levels -

<b>Key result</b> false	
<b>Dose descriptor</b> NOAEL	
Effect level	
250	mg/kg bw/day (actual dose received)
<b>Based on</b> test mat.	
Sex male/female	

Basis for effect level

other: see 'Remark'

At 1,000 mg/kg bw/day, ptosis and decreased locomotor activity were observed in both sexes. At the same dose, histopathological examinations revealed centrilobular hypertrophy of hepatocytes in the liver and increased extramedullary hematopoiesis in the spleen in both sexes.

# Target system / organ toxicity -

**Key result** false

Critical effects observed not specified

# Any other information on results incl. tables

Figures and Tables (in English) are available in the following full report of the study.

http://dra4.nihs.go.jp/mhlw\_data/home/pdf/PDF119 -33 -5c.pdf

# Applicant's summary and conclusion

# Conclusions

In this study, NOAEL for repeated-dose toxicity was determined to be 250 mg/kg bw/day in male and female rats.

# **Executive summary**

A reproduction/developmental toxicity screening test was performed according to OECD TG 421. Male and female rats (12 animals/sex/dose) were administered 2-nitro-p-cresol at 0, 60, 250, and 1,000 mg/ kg bw/day. Males were dosed for 42 days, including a 14 day pre-mating and mating periods. Females were dosed for 42–47 days, including a 14 day pre-mating, mating, and gestation periods, and the time until lactation day 4. At 1,000 mg/kg bw/day, ptosis and decreased locomotor activity were observed in both sexes. At the same dose, histopathological examinations revealed centrilobular hypertrophy of hepatocytes in the liver and increased extramedullary hematopoiesis in the spleen in both sexes. On the basis of these changes, NOAEL for repeated-dose toxicity was determined to be 250 mg/kg bw/day in male and female rats.

# Genetic toxicity in vitro

### ENDPOINT\_STUDY\_RECORD: Genetic toxicity in vitro.001

UUID: IUC5-052223da-12ec-41a9-9c66-24acf10465ce

**Dossier UUID:** 

Author:

Date: 2022-12-16T14:28:45.851+09:00

**Remarks:** 

# Administrative data -

### Endpoint

in vitro gene mutation study in bacteria Type of genotoxicity: gene mutation

**Type of information** experimental study

Adequacy of study key study

Robust study summary false

**Used for classification** false

**Used for SDS** false

**Reliability** 1 (reliable without restriction)

Rationale for reliability incl. deficiencies other: GLP guideline study

# Data source -

### Reference

Reverse mutation test of 2-nitro-p-cresol in Bacteria / MHLW, Japan / study report

Data access data published

# Materials and methods

### Test guideline

**Qualifier** according to guideline

### Guideline

OECD Guideline 471 (Bacterial Reverse Mutation Assay) in vitro gene mutation study in bacteria

# GLP compliance

yes

# Type of assay

bacterial reverse mutation assay in vitro gene mutation study in bacteria

# Test material -

# **Test material information**

2-Nitro-p-cresol

# Method

# Species / strain

# Species / strain / cell type

S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and E. coli WP2 bacteria

# Metabolic activation

with and without

Metabolic activation system S9 mix

# Test concentrations with justification for top dose

Dose-range finding test (-S9 mix and +S9 mix): 0 (vehicle), 1.22, 4.88, 19.5, 78.1, 313, 1250, and 5000 µg/plate;

Main bacterial reverse mutation test (-S9 mix and +S9 mix): 0 (vehicle), 39.1-5000 µg/plate [1st]. 0 (vehicle), 19.5-5000 µg/plate [2nd]. 0 (vehicle), 19.5-1250 µg/plate [3rd, TA98].

# Vehicle / solvent

- Vehicle(s)/solvent(s) used: DMSO

- Justification for choice of solvent/vehicle: The test substance was soluble in DMSO, but not in water.

# Controls

Untreated negative controls

Negative solvent / vehicle controls yes

True negative controls yes tests without all strains

Positive controls yes

Positive control substance sodium azide benzo(a)pyrene furylfuramide other: 2-aminoanthracene, 2-methoxy-6-chloro-9-[3-(2-chloroethyl)-aminopropylamino]acridine-2HCl

Details on test system and experimental conditions

METHOD OF APPLICATION: Preincubation

DURATION - Preincubation period: 20 min - Exposure duration: ca. 50 hours

NUMBER OF REPLICATIONS: 3

DETERMINATION OF CYTOTOXICITY - Method: Cell growth

### **Evaluation criteria**

Criteria for determining a positive result were as follows; A 2–fold or more increase in the number of revertant colonies compared with the solvent control, a concentration–related increase in the nu mber of revertant colonies, and a reproducible increase in the number of revertant colonies.

### Statistics

No statistic method was used for judging of results.

# Results and discussion -

Test results
Key result false
<b>Species / strain</b> S. typhimurium TA 1535, TA 1537, TA 98 and TA 100 bacteria
Metabolic activation with and without
Genotoxicity negative
Cytotoxicity / choice of top concentrations cytotoxicity see tables.
Vehicle controls validity valid
Untreated negative controls validity not examined
Positive controls validity valid
Key result false
<b>Species / strain</b> E. coli WP2 uvr A bacteria
Metabolic activation with and without
Genotoxicity negative
Cytotoxicity / choice of top concentrations cytotoxicity see tables.

### Vehicle controls validity valid

Untreated negative controls validity not examined

**Positive controls validity** valid

# Additional information on results

TEST-SPECIFIC CONFOUNDING FACTORS

Precipitation: Precipitation was not observed on any plates with/without metabolic activation.
 Other effects: coloring was observed on plates with concentration of 1250 µg/plate or more with/w ithout metabolic activation in range-finding studies.

# RANGE-FINDING/SCREENING STUDIES:

In range-finding studies, growth inhibition was observed on plates with concentration of 1250  $\mu$ g/ plate or more in all S. typhimurium strains with/without metabolic activation and on plates with concentration of 5000  $\mu$ g/plate in all E.coli strains with/without metabolic activation. COMPARISON WITH HISTORICAL CONTROL DATA:

In all test conditions and in all tested strains, the number of revertant colonies of solvent controls and positive controls were within the range of historical control data.

# **Remarks on result**

other: all strains/cell types tested Migrated from field 'Test system'.

# **Overall remarks, attachments**

### **Overall remarks**

Figures and Tables (in Japanease) are available in the following full report of the study.

http://dra4.nihs.go.jp/mhlw\_data/home/pdf/PDF119 -33 -5e.pdf

Tables (in English) are attachted to this document. Please download the export file to see the Tables.

### Attachments

Attached (sanitised) documents for publication 119-33-5\_Ames Tables.xlsx / 40.077 KB (application/vnd.openxmlformatsofficedocument.spreadsheetml.sheet)

# Applicant's summary and conclusion

**Conclusions** Interpretation of results (migrated information): negative

### Executive summary

In a bacterial reverse mutation assay using S. typhimuriumTA100, TA1535, TA98, and TA1537 and E. coli WP2uvrA (OECD TG 471), 2-nitro-p-cresol was negative with or without metabolic activation.

### ENDPOINT\_STUDY\_RECORD: Genetic toxicity in vitro.002

UUID: IUC5-05fb6ad5-c084-4f39-96a2-3ec8deffac01

**Dossier UUID:** 

Author:

Date: 2022-12-16T14:29:34.047+09:00

**Remarks:** 

# Administrative data -

### Endpoint

in vitro cytogenicity / chromosome aberration study in mammalian cells Type of genotoxicity: chromosome aberration

Type of information

experimental study

Adequacy of study key study

Robust study summary false

**Used for classification** false

**Used for SDS** false

**Reliability** 1 (reliable without restriction)

**Rationale for reliability incl. deficiencies** other: OECD Test Guideline study under GLP condition

# Data source –

# Reference

In Vitro Chromosomal Aberration Test of 2-nitro-p-cresol on Cultured Chinese Hamster Cells. / MHLW, Japan / study report

Data access data published

# Materials and methods

# Test guideline

**Qualifier** according to guideline

### Guideline

OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test) in vitro cytogenicity / chromosome aberration study in mammalian cells

### **Deviations**

no

**Qualifier** according to guideline

**Guideline** JAPAN: Guidelines for Screening Mutagenicity Testing Of Chemicals

Deviations no

GLP compliance yes

**Type of assay** in vitro mammalian chromosome aberration test chromosome aberration

# Test material

Test material information 2-Nitro-p-cresol

# Method

Target gene Chromosome

Species / strain

**Species / strain / cell type** other: Chinese hamster lung(CHL/IU) cells

Metabolic activation with and without

### Metabolic activation system

rat liver, induced by phenobarbital and 5,6-benzoflavone

# Test concentrations with justification for top dose

-S9 mix (short-term treatment): 0, 25.0, 50.0, 100, 200, 400 ug/mL +S9 mix (short-term treatment): 0, 25.0, 50.0, 100, 200, 400 ug/mL +S9 mix (short-term treatment, confirmation test): 0, 300, 400, 500, 600, 700, 800 ug/mL -S9 mix (continuous treatment, 24 h): 0, 25.0, 50.0, 100, 200, 400 ug/mL -S9 mix (continuous treatment, 48 h): 0, 25.0, 50.0, 100, 200, 400 ug/mL

### Vehicle / solvent

- Vehicle(s)/solvent(s) used: DMSO

### Controls

Untreated negative controls no

Negative solvent / vehicle controls yes True negative controls no

Positive controls yes

**Positive control substance** cyclophosphamide mitomycin C

**Remarks** mitomycin C (without S9 mix), cyclophosphamide (with S9 mix)

# Details on test system and experimental conditions

METHOD OF APPLICATION: Exposure duration: [continuous treatment]: 24, 48 hrs [short-term t reatment]:6 hrs + 18 hr SPINDLE INHIBITOR: Colcemid NUMBER OF REPLICATIONS: 2 NUMBER OF CELLS EVALUATED: 200 cells / dose DETERMINATION OF CYTOTOXICITY - Method: relative total growth

# **Evaluation criteria**

For the evaluation of the frequencies of structural aberrations and of polyploidy induced, the following criteria were employed. Appearance incidence of cells with chromosomal aberrations: Negative (-): < 5%; equivocal (±): 5-10%;

positive (+): > 10%. Finally, the substance is positive when the incidence is considered to be does related and range.

Finally, the substance is positive when the incidence is considered to be dose-related and repro ducible.

### Statistics

not used.

# **Results and discussion**

### Test results

**Key result** false

Species / strain other: Chinese hamster lung (CHL/IU) cells

Metabolic activation with

**Genotoxicity** positive structural aberration

**Cytotoxicity / choice of top concentrations** cytotoxicity 50% cell growth inhibition: 190.0 ug/mL (short)

Vehicle controls validity valid

Untreated negative controls validity not examined

**Positive controls validity** valid

Key result false Species / strain other: Chinese hamster lung (CHL/IU) cells **Metabolic activation** without Genotoxicity negative Cytotoxicity / choice of top concentrations cytotoxicity 50% cell growth inhibition: 192.3 ug/mL (short), 252.6 ug/mL (24h continuous) and 200.0 ug/mL (48h continuous) Vehicle controls validity valid Untreated negative controls validity not examined **Positive controls validity** valid

# **Overall remarks, attachments**

# **Overall remarks**

Figures and Tables (in English) are available in the following full report of the study.

http://dra4.nihs.go.jp/mhlw\_data/home/pdf/PDF119 -33 -5f.pdf

# Applicant's summary and conclusion

# **Executive summary**

An in vitro chromosomal aberration test using CHL/IU cells (OECD TG 473) showed positive result with metabolic activation.

# Genetic toxicity in vivo

# ENDPOINT\_STUDY\_RECORD: Genetic toxicity in vivo.001

UUID: IUC5-40365d06-5dac-40cf-a914-51fc7eacba50

# **Dossier UUID:**

Author:

Date: 2022-12-16T14:30:38.531+09:00

Remarks:

# Administrative data -

# Endpoint

in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus Type of genotoxicity: chromosome aberration

Adequacy of study key study

Robust study summary false

**Used for classification** false

**Used for SDS** false

**Reliability** 1 (reliable without restriction)

Rationale for reliability incl. deficiencies other: OECD Guideline study under GLP condition

# Data source -

# Reference

Micronucleous test of 2-nitro-p-cresol on mouse / MHLW, Japan / study report

# Materials and methods -

### Test guideline

**Qualifier** according to guideline

### Guideline

OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test) in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus

Deviations not specified

Qualifier according to guideline

Guideline

other: Testing Methods for New Chemical Substances etc.

**Deviations** not specified

# GLP compliance

yes (incl. QA statement)

# Type of assay

micronucleus assay chromosome aberration

# Test material

Test material information 2-Nitro-p-cresol

# Test animals

Species

mouse

Strain other: Crlj: CD1(ICR)

Sex

male

### **Details on test animals or test system and environmental conditions** TEST ANIMALS

- Source: Charles River Laboratories Japan, Inc. Atsugi Farm Center
- Age at study initiation: 8 weeks old
- Weight at study initiation: 31.2-36.1 g
- Assigned to test groups randomly: yes
- Housing: White flake (Charles River Japan, Inc.) in plastic cage (W 155 x K 245 x H 150mm: Clea
- Japan, Inc.) - Diet: ad libitum
- Water: ad libitum
- Acclimation period: 8 days

# ENVIRONMENTAL CONDITIONS

- Temperature (°C):21-23
- Humidity (%):47-67
- Air changes: 10-15/h
- Photoperiod: 12 h dark/ 12 h light (light time: 7:00 to 19:00)

# Administration / exposure -

# Route of administration

oral: gavage

### Vehicle

- Vehicle(s)/solvent(s) used: olive oil
- Concentration of test material in vehicle: 0, 25, 50, and 100 mg/mL
- Amount of vehicle (if gavage or dermal): 10 mL/kg bw
- Lot/batch no. (if required): 0420, 0929

# **Details on exposure**

PREPARATION OF DOSING SOLUTIONS:

Dosing solutions were prepared by dissolving the test substance in olive oil. They were used within 6 days.

# **Duration of treatment / exposure** 24 h

**Frequency of treatment** Twice, 24 h interval

### Doses / concentrations

### Remarks

Doses / Concentrations: 0 (vehicle), 250, 500, and 1000 mg/kg bw Basis: actual ingested

### No. of animals per sex per dose

5 males/dose

**Control animals** yes, concurrent vehicle

### Positive control(s)

Mitomycin C (MMC)

- Justification for choice of positive control: MMC is widely used in the micronucleus test and is one of the positive control materials exemplified and recommended in the applicable guidelines.

- Route of administration: intraperitoneal injection

- Doses / concentration: 1 mg/kg bw

# **Examinations** -

### Tissues and cell types examined

Polychromatic erythrocytes from the femur bone marrow

### Details of tissue and slide preparation

TREATMENT AND SAMPLING TIMES (in addition to information in specific fields): Cells for specimen were collected 24 h after the administration.

DETAILS OF SLIDE PREPARATION: Cell suspensions were expanded on the slide glass and dried. The expanded cells were stained using a cover glass with a small amount of acridine orange solution (40ug/mL).

METHOD OF ANALYSIS: fluorescence microscopy, blind method

### **Evaluation criteria**

Criterion for determining a positive result: A dose-related increase in the number of micronucleated cells.

### Statistics

The number of micronucleated polychromatic erythrocytes was determined by the Kastenbaum and Bowman method, and Cochran Armitage test;

Ratio of polychromatic erythrocytes to whole erythrocytes by Bartlett's test and Dunnett's test

# **Results and discussion**

Test results
Key result
false
Sex
male
Genotoxicity
negative
Vehicle controls validity
valid

**Positive controls validity** valid

# Additional information on results

RESULTS OF RANGE-FINDING STUDY

- Dose range: 250, 500, 1000, 2000 mg/kg bw for males and females

- Clinical signs of toxicity in test animals: Death was observed in one male and one female at 2000

mg/kg bw. Colored urine and lowered body weight were observed in all animals dosed.

- Harvest times: 24 h after the treatment

### RESULTS OF DEFINITIVE STUDY

- Induction of micronuclei (for Micronucleus assay): Males: The number of micronucleated cells in all dosed groups was within the range of control. Females: The study was not conducted because no se x differences were found in the preliminary study.

- Ratio of PCE/NCE (for Micronucleus assay): Ratios for dose levels, 0, 250, 500, and 1000 mg/kg bw/ day: 0.13%, 0.13%, 0.16%, and 0.11%; Positive control: 2.54%

# **Overall remarks, attachments**

### **Overall remarks**

Figures and Tables (in English) are available in the following full report of the study.

http://dra4.nihs.go.jp/mhlw\_data/home/pdf/PDF119 -33 -5g.pdf

# Applicant's summary and conclusion

### Conclusions

Interpretation of results (migrated information): negative The test substance did not produce micronuclei in the immature erythrocytes of the test species.

### **Executive summary**

The result of an in vivo micronucleus study (OECD TG 474) was negative up to the maximum tolerated dose (1,000 mg/kg bw/day for 2 days) in mice.

# **Toxicity to reproduction**

# ENDPOINT\_STUDY\_RECORD: Toxicity to reproduction.001

UUID: IUC5-8f5a4886-495c-4d75-a80e-240dc9bce661

**Dossier UUID:** 

Author:

Date: 2022-12-16T14:31:56.759+09:00

**Remarks:** 

# Administrative data

### Endpoint

screening for reproductive / developmental toxicity based on test type (migrated information)

Type of information experimental study

Adequacy of study key study

Robust study summary false

**Used for classification** false

Used for SDS false

**Reliability** 1 (reliable without restriction)

**Rationale for reliability incl. deficiencies** other: OECD Test Guideline study under GLP condition

### **Cross-reference**

Reason / purpose for cross-reference reference to same study

**Remarks** 7.5.1 Repeated dose toxicity: oral.002

# Data source -

### Reference

A reproduction/developmental toxicity screening test in rats treated orally with 2-nitro-p-cresol / MHLW, Japan / study report

Data access data published

# Materials and methods

# Test guideline

Qualifier according to guideline

Guideline

other: OECD TG 421: Reproduction/developmental toxicity screening test

Deviations no

GLP compliance yes

Limit test no

# Test material -

Test material information 2-Nitro-p-cresol

# Test animals -

Species rat

Strain other: Crl:CD(SD)

**Sex** male/female

# Details on test animals or test system and environmental conditions

TEST ANIMALS

- Source: Charles River Laboratories Japan, Inc. Tsukuba
- Age at study initiation: 10 weeks
- Weight at study initiation: Males: 392-474 (average 427) g; Females: 238-297 (average 270) g
- Housing: Steel wire-mesh cage (250 mm x 350 mm x 200 mm )
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 19 days

ENVIRONMENTAL CONDITIONS

- Temperature (°C): 20-24
- Humidity (%): 33-69
- Air changes: 10-15 times / hr
- Photoperiod: 12 hrs dark / 12 hrs light (07:00-19:00)

# Administration / exposure

**Route of administration** oral: gavage
### Vehicle

olive oil

#### **Details on mating procedure**

- M/F ratio per cage:1:1
- Length of cohabitation:up to 14 days
- Proof of pregnancy: [vaginal plug / sperm in vaginal smear] referred to as [day 0] of pregnancy

#### Analytical verification of doses or concentrations

yes

#### Duration of treatment / exposure

(P) Males: 42 days including 14 days pre-mating and mating periods, and thereafter 14 days (P) Femal es: 42-47 days including 14 days pre-mating, mating and gestation periods, and the days until day 4 of lactation. Infertile females: 40-53 days

#### **Frequency of treatment**

Once/day, 7days/week

#### Doses / concentrations

#### Remarks

Doses / Concentrations: 0 (vehicle), 60, 250, and 1000 mg/kg bw/day Basis: actual ingested

#### No. of animals per sex per dose

12 animals/sex/dose

#### **Control animals**

yes, concurrent vehicle

### **Examinations**

#### Parental animals: Observations and examinations

CAGE SIDE OBSERVATIONS: Yes - Time schedule: Males and females: 3 times/day

#### BODY WEIGHT: Yes

- Time schedule for examinations: Males: Days 1, 4, 8, 11, 15, 22, 25, 29, 32, 36, 39, 42, and the day of necropsy Females: Twice a week during the precopulation period (days 1, 4, 8, 11, and 15); gestation days 0, 4, 7, 11, 14, 17, and 20; lactation days 0 and 4; and the day of necropsy. For unmating females, 18, 22 and 25 in the mating period

FOOD CONSUMPTION: Yes Males: Days 1, 4, 8, 11, 15, 32, 36, 39, and 42 in dosing period Females: Days 1, 4, 8, 11, and 15; gestation days 1, 4, 7, 11, 14, 17, and 20; lactation days 2 and 4

OTHER: Females: Numbers of corpus luteum and implantation site on the day of necropsy

#### **Oestrous cyclicity (parental animals)**

Vaginal smears were collected from all females in the main groups and microscopically examined every day from the day after the start of administration until the day copulation was confirmed. During the pre-mating administration period, vaginal smear pictures were classified as proestrus, estrus, metestrus or diestrus and examined for the frequency of estrus and interval between estruses (estrous cycle). During the mating period, vaginal smears were examined for the presence of sperm.

#### Sperm parameters (parental animals)

Parameters examined in P male parental generations: testes weight, epididymides weight

#### Litter observations

PARAMETERS EXAMINED: The following parameters were examined in F1 offspring [number and sex of pups, stillbirths, live births, postnatal mortality, presence of gross anomalies, and weight]. GROSS EXAMINATION OF DEAD PUPS: Yes, for external and internal abnormalities.

#### Postmortem examinations (parental animals)

SACRIFICE:

Male animals: Rats were euthanized by exsanguination under ether anesthesia on the day after the l ast administration.

Maternal animals: Rats were euthanized by exsanguination under ether anesthesia on day 4 of lactati on.

#### GROSS PATHOLOGY: Yes (see tables)

HISTOPATHOLOGY: Yes (epididymis, prostate, seminal vesicle, testis, ovary, uterus, vagina, and gross abnormal sites)

ORGAN WEIGHTS, Yes: Testes and epididymis

#### Postmortem examinations (offspring)

GROSS NECROPSY

- Gross necropsy consisted of external and internal examinations including the cervical, thoracic, and abdominal viscera.

#### Statistics

The data were analyzed for homogeneity of variance by the Bartlett test. If variances were homogeneous, data was analyzed by the Dunnett test, whereas heterogeneous data was analyzed by the Steel test (p<0.05, two-sided).

2 groups: The data were analyzed for homogeneity of variance by the F test. If variances were hom ogeneous, data was analyzed by the Student t test, whereas heterogeneous data was analyzed by the Aspin-Welch t test (p<0.05, two-sided).

Especially,

Implantation index, Stillborn index, Liveborn index, External abnormalities, Viability index: the Steel test (p<0.05 and <0.01, two-sided)

Copulation index, Fertility index, Insemination index, Delivery index: Fisher's exact test (p<0.05 and <0.01, two-sided)

#### **Reproductive indices**

Each parameter was determined by the following equations: Copulation index (%) = (No. of copulated animals/No. of co-housed animals) × 100 Fertility index (%) = (No. of pregnant females/No. of copulated females) × 100 Insemination index (%) = (No. of pregnant females/No. of copulated males) × 100 Duration of gestation (days) = day 0 of lactation – day 0 of gestation Delivery index (%) = (No. of females delivered liveborn pups/No. of pregnant females) × 100 Implantation index (%) = (No. of implantation sites/No. of corpora lutea) × 100 Stillborn index (%) = (No. of stillborn pups/Total No. of pups born) × 100 Liveborn index (%) = (No. of liveborn pups/Total No. of pups born) × 100 External abnormalities (%) = (No. of pups with external abnormalities/No. of liveborn pups) × 100 Sex ratio = No. of liveborn male pups/(No. of liveborn male pups + No. of liveborn female pups)

#### Offspring viability indices

Viability index (%) = (No. of surviving pus on day 4 after birth/No. of liveborn pups on day 0 after birth) × 100

	Results	and	discussion	
--	---------	-----	------------	--

### Results: P0 (first parental generation)

### General toxicity (P0) -

**Clinical signs** effects observed, treatment-related

**Description (incidence and severity)** see 7.5.1 Repeated dose toxicity: oral.002

**Body weight and weight changes** effects observed, treatment-related

**Description (incidence and severity)** see 7.5.1 Repeated dose toxicity: oral.002

Food consumption and compound intake (if feeding study) effects observed, treatment-related

**Description (incidence and severity)** see 7.5.1 Repeated dose toxicity: oral.002

Organ weight findings including organ / body weight ratios no effects observed

**Description (incidence and severity)** on reproductive organs

**Gross pathological findings** no effects observed

**Description (incidence and severity)** on reproductive organs

Histopathological findings: non-neoplastic no effects observed

**Description (incidence and severity)** on reproductive organs

### Reproductive function / performance (P0) -

**Reproductive function: oestrous cycle** no effects observed

**Reproductive function: sperm measures** not examined

**Reproductive performance** no effects observed

**Description (incidence and severity)** on reproductive organs

### Effect levels (P0) -

<b>Key result</b> false	
<b>Dose descriptor</b> NOAEL	
Effect level	
250	mg/kg bw/day (actual dose received)
<b>Sex</b> male/female	

### Results: F1 generation \_\_\_\_\_

## General toxicity (F1)

**Clinical signs** no effects observed

Mortality / viability no mortality observed

Body weight and weight changes no effects observed

Sexual maturation not examined

Organ weight findings including organ / body weight ratios not examined

**Gross pathological findings** no effects observed

Histopathological findings not examined

### Effect levels (F1) ——

<b>Key result</b> false	
Dose descriptor NOAEL	
Generation F1	
Effect level	
1000	mg/kg bw/day (actual dose received)
<b>Sex</b> male/female	
Basis for effect level other: the highest dose tested	

### **Overall reproductive toxicity** -

**Key result** false

Reproductive effects observed not specified

### Any other information on results incl. tables

Figures and Tables (in English) are available in the following full report of the study.

http://dra4.nihs.go.jp/mhlw\_data/home/pdf/PDF119 -33 -5c.pdf

### Applicant's summary and conclusion

#### Conclusions

NOAEL for the rat reproductive/developmental toxicity of 4-chlorobenzaldehyde was determined to be 200 mg/kg bw/day.

#### **Executive summary**

In the reproduction/developmental toxicity screening test (0, 60, 250, and 1,000 mg/kg bw/day) (OECD TG 421), no effects of this substance on reproductive and developmental parameters were observed at 1,000 mg/kg bw/day. NOAEL for the rat reproductive/developmental toxicity of 2-nitro-p-cresol was determined to be 1,000 mg/kg bw/day, the highest dose tested.

### DOMAIN

### Substance

### SUBSTANCE: 2-Nitro-p-cresol

UUID: IUC5-b0a94a30-717c-4d02-af0c-412c12b4d472

Dossier UUID:

Author:

Date: 2022-12-16T14:32:04.949+09:00

**Remarks:** 

Substance name 2-Nitro-p-cresol

**Legal entity** National Institute of Health Sciences / Kawasaki / Japan

### Identification of substance

Reference substance 2-nitro-p-cresol / 4-methyl-2-nitrophenol / 119-33-5 / 204-315-6

EC numberEC name204-315-6EC InventoryCAS numberCAS name119-33-5IUPAC name4-methyl-2-nitrophenol

### Role in the supply chain

Manufacturer false

**Importer** false

**Only representative** false

**Downstream user** false

# References

## **Reference Substances**

### **REFERENCE\_SUBSTANCE: 2-nitro-p-cresol**

UUID: ECB5-4c8b7908-3640-47d4-b274-fae78201d6fd

**Dossier UUID:** 

Author:

Date: 2018-08-27T10:55:22.000+09:00

**Remarks:** 

**Reference substance name** 2-nitro-p-cresol

IUPAC name 4-methyl-2-nitrophenol

### Inventory

#### **Inventory number**

Inventory name 2-nitro-p-cresol

Inventory EC Inventory

Inventory number 204-315-6

**CAS number** 119-33-5

Molecular formula C7H7NO3

Description

**CAS number** 119-33-5

### Synonyms

#### Synonyms

Identity 2-nitro-p-cresol

Identity Phenol, 4-methyl-2-nitro-

### Molecular and structural information

#### Molecular formula C7H7NO3

#### Molecular weight

153.1354

#### SMILES notation Cc1ccc(0)c(c1)[N+](=0)[0-]

InChi

InChI=1/C7H7NO3/c1-5-2-3-7(9)6(4-5)8(10)11/h2-4,9H,1H3

### Structural formula



### Related substances

**Group / category information** OECD Category: m,p - Cresols USEPA Category: Phenols

# **Test Materials**

### **TEST\_MATERIAL\_INFORMATION: 2-Nitro-p-cresol**

UUID: 122b9bdd-68e3-3539-adbb-7378661ed03e

**Dossier UUID:** 

Author:

Date: 2022-12-15T09:17:52.446+09:00

Remarks:

Name 2-Nitro-p-cresol

### Composition

Composition

**Type** Constituent

Reference substance
2-nitro-p-cresol / 4-methyl-2-nitrophenol / 119-33-5 / 204-315-6

EC numberEC name204-315-6EC InventoryCAS numberCAS name119-33-5IUPAC name4-methyl-2-nitrophenol

### Other characteristics -

#### Details on test material

- Name of test material (as cited in study report): 2-nitro-p-cresol
- Purity: 99.6%
- Lot/batch No.: FHD01
- Stability under test conditions: Stable
- Storage condition of test material: a cool (3-6 °C) and dark place (in a refrigerator), with an airtight stopper
- Dosing solution storage condition: under a cool (3-6 °C) place (in a refrigerator), in a brown glass bo ttle
- Other: The dosing solution was used within 7 days of preparation.

### **TEST\_MATERIAL\_INFORMATION: 2-Nitro-p-cresol**

UUID: 5bf89a9f-610d-3117-9884-daae68efa128

**Dossier UUID:** 

Author:

Date: 2022-12-15T09:16:41.786+09:00

Remarks:

Name

2-Nitro-p-cresol

### Composition

Composition

**Type** Constituent

Reference substance 2-nitro-p-cresol / 4-methyl-2-nitrophenol / 119-33-5 / 204-315-6

EC number	EC name
204-315-6	EC Inventory
CAS number	CAS name
119-33-5	
IUPAC name	
4-methyl-2-nitrophenol	

### Other characteristics -

#### Details on test material

- Name of test material (as cited in study report): 2-Nitro-p-cresol

- Analytical purity: 99.8%
- Lot No.: FBR01
- Storage condition of test material: at a cold (temperature 2-6  $^\circ \! C$ ) and dark place, with airtight stopper.

- Stability under test conditions: The stability of test material was identified by analysis of the remainder.

# Literatures

# LITERATURE: A reproduction/developmental toxicity screening test in rats treated orally with 2-nitro-p-cresol

UUID: cdbb7871-31c4-3a0d-8a4b-bf954b375559

**Dossier UUID:** 

Author:

Date: 2017-02-15T15:43:40.000+09:00

**Remarks:** 

### **General information**

### Reference Type

study report

Title

A reproduction/developmental toxicity screening test in rats treated orally with 2-nitro-p-cresol

Author MHLW, Japan

Year

2012

### Bibliographic source

available in the web of Japan Existing Chemical Data Base (JECDB) at http://dra4.nihs.go.jp/ mhlw\_data/jsp/SearchPageENG.jsp

### Testing facility

BoZo Research Center

### LITERATURE: In Vitro Chromosomal Aberration Test of 2nitro-p-cresol on Cultured Chinese Hamster Cells.

UUID: 8a48dba7-f670-3547-8ad5-6a6f48a27e32

Dossier UUID:

Author:

Date: 2017-02-15T15:41:24.000+09:00

**Remarks:** 

### General information

#### Reference Type

study report

#### Title

In Vitro Chromosomal Aberration Test of 2-nitro-p-cresol on Cultured Chinese Hamster Cells.

Author MHLW, Japan

**Year** 2007

#### **Bibliographic source**

available in the web of Japan Existing Chemical Data Base (JECDB) at http://dra4.nihs.go.jp/mhlw\_data/jsp/SearchPageENG.jsp

### Testing facility

BoZo Research Center

# LITERATURE: Micronucleous test of 2-nitro-p-cresol on mouse

UUID: 322a5a3a-eb01-3870-ada3-90cdba50efff

**Dossier UUID:** 

Author:

Date: 2017-02-15T15:42:10.000+09:00

**Remarks:** 

### **General information**

### Reference Type

study report

Title

Micronucleous test of 2-nitro-p-cresol on mouse

**Author** MHLW, Japan

**Year** 2011

#### **Bibliographic source**

available in the web of Japan Existing Chemical Data Base (JECDB) at http://dra4.nihs.go.jp/mhlw\_data/jsp/SearchPageENG.jsp

Testing facility

Bozo Research Center

# LITERATURE: Reverse mutation test of 2-nitro-p-cresol in Bacteria

UUID: 99e619c7-c952-31c2-9687-ca7d8c11d691

**Dossier UUID:** 

Author:

Date: 2022-12-15T09:31:25.733+09:00

**Remarks:** 

### **General information**

### Reference Type

study report

Title

Reverse mutation test of 2-nitro-p-cresol in Bacteria

**Author** MHLW, Japan

**Year** 2007

#### **Bibliographic source**

available in the web of Japan Existing Chemical Data Base (JECDB) at http://dra4.nihs.go.jp/mhlw\_data/jsp/SearchPageENG.jsp

### **Testing facility**

Bozo Research Center Inc.

### LITERATURE: Single Dose Oral Toxicity Test of 2-nitro-pcresol in Rats

UUID: c35179d9-e9d1-4f83-8fea-4e8e3cfe7be7

**Dossier UUID:** 

Author:

Date: 2018-08-24T16:59:16.000+09:00

**Remarks:** 

### General information

Reference Type study report

**Title** Single Dose Oral Toxicity Test of 2-nitro-p-cresol in Rats

Author MHLW, japan

**Bibliographic source** Single Dose Oral Toxicity Test of 2-nitro-p-cresol in Rats

### LITERATURE: Twenty-eight-day Repeat Dose Oral Toxicity Test of 2-Nitro-p-cresol in Rats

UUID: 498a7463-633b-3f3e-93d5-83ac8e71b5bd

**Dossier UUID:** 

Author:

Date: 2022-12-15T09:31:07.197+09:00

**Remarks:** 

### **General information**

### Reference Type

publication

### Title

Twenty-eight-day Repeat Dose Oral Toxicity Test of 2-Nitro-p-cresol in Rats

Author MHLW, Japan

## **Year** 2011

### **Bibliographic source**

available in the web of Japan Existing Chemical Data Base (JECDB) at http://dra4.nihs.go.jp/mhlw\_data/jsp/SearchPageENG.jsp

### **Testing facility**

Research institute for animal science in biochemistry and toxicology (RIAS)

# **Legal Entities**

### **LEGAL\_ENTITY: National Institute of Health Sciences**

UUID: IUC4-b036ff75-0f3c-323b-b200-ed5f46cf5101

**Dossier UUID:** 

Author:

Date: 2022-11-07T15:49:29.000+09:00

**Remarks:** 

### General information -

#### Legal entity name

National Institute of Health Sciences

#### Remarks

Disclaimer: The contents in this document were created based on the MHLW (Ministry of Health, Labour and Welfare) peer reviewed study reports (in Japanese) in JECDB (Japan Existing Chemical Database) at http://dra4.nihs.go.jp/mhlw\_data/jsp/SearchPageENG.jsp. Authorship is in the Division of Risk Assessment, the National Institute of Health Sciences, and the contents do not reflect any o fficial MHLW opinions or any other regulatory policies.

### Address -

Address 1 Tonomachi 3-25-26

**Address 2** Kawasaki-ku

Postal code 210-9501

**Town** Kawasaki

**Region / State** Kanagawa

**Country** Japan JP

### Identifiers -

Other IT system identifiers

<b>IT system</b> LEO			
<b>ID</b> 10767			
<b>IT system</b> IUCLID4			